Everolimus-eluting versus sirolimus-eluting stents: An updated meta-analysis of randomized trials

Clinical Research in Cardiology

Volumn 101, Issue 6, 2012, Pages 461-467

  De Waha, Antoinette ^a   Cassese, Salvatore ^a   Park, Duk Woo ^b   Burzotta, Francesco ^c   Byrne, Robert A ^a   Tada, Tomohisa ^a   King, Lamin A ^a   Park, Seung Jung ^c   Schömig, Albert ^a   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b University of Ulsan College of Medicine   (South Korea)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Death; Everolimus eluting; Sirolimus eluting stent; Stent thrombosis

Indexed keywords

EVEROLIMUS; RAPAMYCIN;

ARTICLE; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; HEART DISEASE; HUMAN; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863727791     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-012-0414-8     Document Type: Article

References (31)

1. Zahn R, Hamm CW, Schneider S, Zeymer U, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Nienaber CA, Pfannebecker T, Senges J (2007) The sirolimus-eluting coronary stent in daily routine practice in germany: trends in indications over the years. Results from the prospective multi-centre german cypher stent registry. Clin Res Cardiol 96:548-556
2. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schömig A (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:1030-1039
3. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370:937-948
4. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356:998-1008
5. de Waha A, Dibra A, Kufner S, Baumgart D, Sabate M, Maresta A, Schömig A, Kastrati A (2011) Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials. Clin Res Cardiol 100:561-570
6. Dibra A, Tiroch K, Schulz S, Kelbaek H, Spaulding C, Laarman GJ, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Campo G, Thuesen L, Vink MA, Schalij MJ, Violini R, Schomig A, Kastrati A (2010) Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clin Res Cardiol 99:345-357
7. Kukreja N, Onuma Y, Serruys PW (2009) Xience v everolimuseluting coronary stent. Expert Rev Med Devices 6:219-229
8. Wohrle J, Rottbauer W, Imhof A (2011) Everolimus-eluting stents for treatment of chronic total coronary occlusions. Clin Res Cardiol 101:23-28
9. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC (2010) Second-generation everolimuseluting and paclitaxel-eluting stents in real-life practice (compare): A randomised trial. Lancet 375:201-209
10. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrie D, Thuesen L, Boone E, Miquel- Herbert K, Daemen J (2006) A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the spirit ii trial. Eurointervention 2:286-294
11. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ (2008) Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299:1903-1913
12. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ (2010) Everolimus-eluting versus paclitaxeleluting stents in coronary artery disease. N Engl J Med 362:1663-1674
13. Schömig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A (2007) A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxeleluting stents in patients with coronary artery disease. J Am Coll Cardiol 50:1373-1380
14. de Waha A, Dibra A, Byrne RA, Ndrepepa G, Mehilli J, Fusaro M, Laugwitz KL, Massberg S, Schomig A, Kastrati A (2011) Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv 4:371-377
15. Kimura T: One-year clinical and angiographic outcomes from the reset trial - randomized evaluation of sirolimus-eluting versus everolimus-eluting stent trial. Presented at the ESC in August 2011
16. Burzotta F, Trani C, Todaro D, Mariani L, Talarico GP, Tommasino A, Giammarinaro M, Niccoli G, Porto I, Leone AM, Mongiardo R, Mazzari MA, Schiavoni G, Crea F (2011) Prospective randomized comparison of sirolimus- or everolimuseluting stent to treat bifurcated lesions by provisional approach. JACC Cardiovasc Interv 4:327-335
17. Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Seung KB, Yang TH, Lee SG, Lee JH, Seong IW, Cheong SS, Lee BK, Lee NH, Lee K, Kim HS, Jeon DS, Kim MK, Nah DY, Tahk SJ, Park SJ (2011) Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: A randomized longdes- III (percutaneous treatment of long native coronary lesions with drug-eluting stent-iii) trial. JACC Cardiovasc Interv 4:1096-1103
18. Byrne RA, Kastrati A, Massberg S, Wieczorek A, Laugwitz KL, Hadamitzky M, Schulz S, Pache J, Fusaro M, Hausleiter J, Schömig A, Mehilli J (2011) Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: three-year outcomes from a randomized clinical trial. J Am Coll Cardiol 58:1325-1331
19. Jensen LO (2010) Sort out 4: a prospective randomized trial of everolimus-eluting stents and sirolimus-eluting stents in patients with coronary artery disease. Presented at the Transcatheter Cardiovascular Therapeutics meeting, September 2010
20. Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La HP, Rocca, Ricard I, Pfisterer M (2010) Drug-eluting versus baremetal stents in large coronary arteries. N Engl J Med 363:2310-2319
21. Kim WJ, Lee SW, Park SW, Kim YH, Yun SC, Lee JY, Park DW, Kang SJ, Lee CW, Lee JH, Choi SW, Seong IW, Lee BK, Lee NH, Cho YH, Shin WY, Lee SJ, Lee SW, Hyon MS, Bang DW, Park WJ, Kim HS, Chae JK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Choi YJ, Cheong SS, Yang TH, Jang JS, Her SH, Park SJ (2011) Randomized comparison of everolimuseluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus: results from essence-diabetes trial. Circulation 124:886-892
22. Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Jo SH, Choi YJ, Hur SH, Kwon HM, Chun DW, Kim BO, Park SH, Lee NH, Jeon HK, Gwon HC, Jang YS, Kim HS (2012) Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the excellent randomized trial. J Am Coll Cardiol (in press)
23. Altman DG, Schulz KF (2001) Statistics notes: concealing treatment allocation in randomised trials. BMJ 323:446-447
24. Juni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:42-46
25. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344-2351
26. Jensen LO, Thayssen P, Tilsted HH, Ravkilde J, Junker A, Hansen HS, Hansen KN, Pedersen KE, Sorensen HT, Thuesen L, Lassen JF (2010) Rationale and design of a randomized clinical comparison of everolimus-eluting (xience v/promus) and sirolimus- eluting (cypher select?) coronary stents in unselected patients with coronary heart disease. Cardiology 116:73-78
27. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267
28. Egger M, Smith GD, Altman D (2001) Systematic reviews in health care: metaanalysis in context. BMJ Publishing, London, p 357
29. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
31. Räber L, Magro M, Stefanini G (2011) Newer generation everolimus- eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents. Presented at the ESC in August 2011